We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+12.16%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$718B
AUM Growth
+$49.7B
Cap. Flow
-$15.6B
Cap. Flow %
-2.17%
Top 10 Hldgs %
31.75%
Holding
3,044
New
123
Increased
1,636
Reduced
968
Closed
150

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$3.11B
2
META icon
Meta Platforms (Facebook)
META
+$2.59B
3
EQT icon
EQT Corp
EQT
+$1.31B
4
CL icon
Colgate-Palmolive
CL
+$1.08B
5
ADBE icon
Adobe
ADBE
+$1.06B

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$1.92B
2
UNH icon
UnitedHealth
UNH
+$1.78B
3
AMD icon
Advanced Micro Devices
AMD
+$1.55B
4
ROST icon
Ross Stores
ROST
+$1.54B
5
ASML icon
ASML
ASML
+$1.49B

Sector Composition

Rank Sector Weight
1 Technology 31.61%
2 Healthcare 16.91%
3 Consumer Discretionary 11.05%
4 Financials 10.6%
5 Communication Services 9.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CMPX icon
2776
Compass Therapeutics
CMPX
$416M
$59K ﹤0.01%
+18,521
New +$58.2K
CTXR icon
2777
Citius Pharmaceuticals
CTXR
$20.7M
$59K ﹤0.01%
1,940
+1,000
+106% +$32.9K
VXRT
2778
DELISTED
Vaxart
VXRT
$58K ﹤0.01%
78,500
-23,480
-23% -$21.8K
DXLG icon
2779
Destination XL Group
DXLG
$33.2M
$57K ﹤0.01%
11,483
+523
+5% +$2.46K
KULR icon
2780
KULR Technology Group
KULR
$142M
$57K ﹤0.01%
10,975
+3,850
+54% +$21.8K
FRGE
2781
DELISTED
Forge Global Holdings
FRGE
$55K ﹤0.01%
+1,488
New +$36.5K
BKSY icon
2782
BlackSky Technology
BKSY
$1.29B
$54K ﹤0.01%
+3,003
New +$35.9K
CRDF icon
2783
Cardiff Oncology
CRDF
$78.6M
$54K ﹤0.01%
36,500
GORO icon
2784
Goldgroup Mining Inc.
GORO
$209M
$54K ﹤0.01%
84,700
STRO icon
2785
Sutro Biopharma
STRO
$356M
$54K ﹤0.01%
+1,155
New +$57.5K
EMKR
2786
DELISTED
Emcore Corp
EMKR
$54K ﹤0.01%
7,160
PED icon
2787
PEDEVCO
PED
$150M
$53K ﹤0.01%
2,875
TSP
2788
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
$53K ﹤0.01%
31,886
+5,630
+21% +$9.11K
AXDX
2789
DELISTED
Accelerate Diagnostics
AXDX
$52K ﹤0.01%
6,390
RYAM icon
2790
Rayonier Advanced Materials
RYAM
$553M
$52K ﹤0.01%
11,923
SLQT icon
2791
SelectQuote
SLQT
$127M
$52K ﹤0.01%
26,400
OTLK icon
2792
Outlook Therapeutics
OTLK
$150M
$51K ﹤0.01%
1,461
RNAC icon
2793
Cartesian Therapeutics
RNAC
$264M
$51K ﹤0.01%
1,516
+789
+109% +$28.2K
FARM
2794
DELISTED
Farmer Brothers
FARM
$49K ﹤0.01%
17,600
-12,800
-42% -$34.5K
IDN icon
2795
Intellicheck
IDN
$75.9M
$49K ﹤0.01%
19,500
XFOR icon
2796
X4 Pharmaceuticals
XFOR
$429M
$49K ﹤0.01%
+834
New +$42.9K
OSG
2797
DELISTED
Overseas Shipholding Group Inc.
OSG
$49K ﹤0.01%
+11,723
New +$45.3K
LTRX icon
2798
Lantronix
LTRX
$277M
$48K ﹤0.01%
11,200
MNOV icon
2799
MediciNova
MNOV
$65.5M
$48K ﹤0.01%
20,700
BRN icon
2800
Barnwell Industries
BRN
$14M
$47K ﹤0.01%
18,200

Similar funds

T. Rowe Price Associates's Q2 2023 Portfolio in Review

As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
  • T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
  • T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
  • T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
  • T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
  • T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
  • T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.